Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold 1,000 shares of common stock on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a transaction involving the company's stock on September 3, 2024.
• McCourt exercised a non-qualified stock option to acquire 1,000 shares of common stock at a price of $381.4 per share.
• Simultaneously, McCourt sold 1,000 shares of common stock at a price of $1,178.73 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 13, 2024.
• Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
• McCourt also holds options to purchase 8,000 shares of Regeneron common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information. These transactions are closely watched by investors for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are standard practice among pharmaceutical companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices of these options are typically benchmarked against industry peers to attract and retain top talent.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their personal finances while avoiding accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates